New Study – TissueCypher® Predicts Development of Esophageal Cancer in Patients with Non-Dysplastic BE

We are excited to announce a newly published clinical study of TissueCypher® performance for predicting development of esophageal cancer in patients with Non-dysplastic Barrett’s Esophagus. The study, Independent Validation of a Tissue Systems Pathology Assay to Predict Future Progression in Nondysplastic Barrett’s Esophagus: A Spatial-Temporal Analysis, was published online in Clinical and Translational Gastroenterology this week.

You can view the entire article here:
https://journals.lww.com/ctg/Fulltext/2020/10000/Independent_Validation_of_a_Tissue_Systems.9.aspx

Study Highlights

• What is known:

• TissueCypher has been shown in past studies to identify nondysplastic Barrett’s patients who are at increased risk of progression. Spatial and temporal variability may affect the performance of the assay.

• What is new here:

• TissueCypher identified high risk non-dysplastic Barrett’s patients who progress at a rate comparable with patients with expert confirmed LGD (6.9% annual progression rate for TC High Risk in this study).
• The assay identified 31% of progressors when assessing a single biopsy level closest to the GEJ at the baseline endoscopy.
• Sensitivity increased to 50% and 69% in spatial and temporal analyses, respectively, while specificity remained at 95%. i.e. Assessing more biopsies increases sensitivity but does not increase number of false positives.
• Assessing biopsies from additional spatial levels and time points increased TissueCypher performance and identified the majority of future progressors.
• This is the fourth clinical study to independently validate the ability of TissueCypher to predict incident progression from non-dysplastic BE to HGD/EAC.

Please don’t hesitate to reach out with any questions or to discuss this.

Source: Cernostics